BEIGENE, LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 153.6 USD | +3.38% |
|
+18.58% | -14.85% |
| Apr. 23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
| Apr. 23 | BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10,134 | 23,494 | 27,843 | 22,843 | 18,862 | 16,048 | - | - |
| Enterprise Value (EV) 1 | 9,392 | 19,361 | 24,097 | 19,511 | 16,564 | 14,566 | 14,917 | 14,713 |
| P/E ratio | -10.5 x | -13.5 x | -17.8 x | -11.3 x | -21.3 x | -18 x | -42.3 x | 49.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 23.7 x | 76.1 x | 23.7 x | 16.1 x | 7.67 x | 5.21 x | 4.09 x | 3.28 x |
| EV / Revenue | 21.9 x | 62.7 x | 20.5 x | 13.8 x | 6.74 x | 4.72 x | 3.8 x | 3.01 x |
| EV / EBITDA | -9.98 x | -11.9 x | -17.3 x | -11.3 x | -14.8 x | -18.2 x | -50.5 x | 31.3 x |
| EV / FCF | -11.2 x | -13.8 x | -15.4 x | -10.7 x | -9.63 x | -16.4 x | -35.1 x | 35.8 x |
| FCF Yield | -8.94% | -7.24% | -6.48% | -9.34% | -10.4% | -6.11% | -2.85% | 2.79% |
| Price to Book | 11.2 x | 5.57 x | 4.03 x | 5.17 x | 5.32 x | 5.16 x | 5.53 x | 5.32 x |
| Nbr of stocks (in thousands) | 61,136 | 90,924 | 102,770 | 103,859 | 104,578 | 104,490 | - | - |
| Reference price 2 | 165.8 | 258.4 | 270.9 | 219.9 | 180.4 | 153.6 | 153.6 | 153.6 |
| Announcement Date | 3/2/20 | 2/25/21 | 2/25/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 428.2 | 308.9 | 1,176 | 1,416 | 2,459 | 3,083 | 3,921 | 4,889 |
| EBITDA 1 | -941.3 | -1,626 | -1,392 | -1,723 | -1,120 | -801.6 | -295.2 | 469.8 |
| EBIT 1 | -959.9 | -1,658 | -1,439 | -1,790 | -1,208 | -934.1 | -403.1 | 254.5 |
| Operating Margin | -224.16% | -536.69% | -122.31% | -126.4% | -49.12% | -30.3% | -10.28% | 5.21% |
| Earnings before Tax (EBT) 1 | -943.6 | -1,618 | -1,439 | -1,961 | -825.8 | -882.4 | -369.4 | 456.6 |
| Net income 1 | -948.6 | -1,597 | -1,413 | -2,004 | -881.7 | -892.3 | -356.5 | 351.5 |
| Net margin | -221.53% | -517.01% | -120.15% | -141.52% | -35.86% | -28.94% | -9.09% | 7.19% |
| EPS 2 | -15.80 | -19.13 | -15.23 | -19.43 | -8.450 | -8.554 | -3.630 | 3.120 |
| Free Cash Flow 1 | -839.9 | -1,401 | -1,562 | -1,822 | -1,719 | -889.9 | -424.4 | 410.7 |
| FCF margin | -196.14% | -453.57% | -132.76% | -128.68% | -69.93% | -28.86% | -10.82% | 8.4% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 87.42% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 116.86% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/25/21 | 2/25/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 206.4 | 214 | 420.4 | 306.6 | 341.6 | 387.6 | 380.1 | 606.4 | 447.8 | 595.3 | 1,043 | 781.3 | 634.4 | 673 | 752.6 | 830.4 | 843.3 | 707.5 |
| EBITDA 1 | -450.1 | -558.6 | - | -426.7 | -423.9 | -422.2 | -450.6 | - | -351.2 | - | - | -112.5 | -565.3 | -406.2 | -202.9 | -198.9 | -150.7 | -115.2 |
| EBIT 1 | -462.3 | -571.7 | - | -443.3 | -439.4 | -438.4 | -468.6 | -907 | -371.3 | -318.7 | -690 | -134 | -589.1 | -346.6 | -238 | -236.5 | -217.4 | -149.6 |
| Operating Margin | -223.95% | -267.19% | - | -144.57% | -128.64% | -113.09% | -123.29% | -149.56% | -82.91% | -53.54% | -66.15% | -17.15% | -92.86% | -51.5% | -31.63% | -28.48% | -25.78% | -21.15% |
| Earnings before Tax (EBT) 1 | -433.1 | -586.8 | - | -421.2 | -557.6 | -551.2 | -431 | -982.2 | -336.9 | -367.5 | -704.4 | 229.3 | -350.8 | -259.4 | -234.3 | -233.3 | -198.2 | - |
| Net income 1 | -413.9 | -585.7 | -999.5 | -434.3 | -571.4 | -557.6 | -445.3 | -998.1 | -348.4 | -381.1 | -729.6 | 215.4 | -367.6 | -264.9 | -243.7 | -237.7 | -207.2 | - |
| Net margin | -200.47% | -273.7% | -237.74% | -141.63% | -167.3% | -143.84% | -117.16% | -164.59% | -77.81% | -64.03% | -69.94% | 27.57% | -57.94% | -39.36% | -32.39% | -28.63% | -24.57% | - |
| EPS 2 | -4.460 | -6.160 | - | -4.240 | -5.560 | -5.390 | -4.290 | - | -3.340 | -3.640 | - | 2.010 | -3.480 | -2.887 | -2.427 | -2.132 | -1.715 | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/25/22 | 2/25/22 | 5/5/22 | 8/4/22 | 11/9/22 | 2/27/23 | 2/27/23 | 5/4/23 | 8/2/23 | 8/2/23 | 11/9/23 | 2/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 742 | 4,132 | 3,746 | 3,332 | 2,297 | 1,482 | 1,131 | 1,334 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -840 | -1,401 | -1,562 | -1,822 | -1,719 | -890 | -424 | 411 |
| ROE (net income / shareholders' equity) | -70.2% | -66.1% | -28% | -38.1% | -22.3% | -28.2% | -15.1% | 13.6% |
| ROA (Net income/ Total Assets) | -49.1% | -44.3% | -19.8% | -26.9% | -14.5% | -18.8% | -10.2% | 6.67% |
| Assets 1 | 1,931 | 3,607 | 7,123 | 7,457 | 6,093 | 4,749 | 3,483 | 5,272 |
| Book Value Per Share 2 | 14.80 | 46.40 | 67.30 | 42.50 | 33.90 | 29.80 | 27.80 | 28.90 |
| Cash Flow per Share 2 | -12.50 | -15.40 | -14.00 | -14.50 | -11.10 | -3.080 | -2.020 | 0.2000 |
| Capex 1 | 89.6 | 118 | 263 | 325 | 562 | 245 | 232 | 260 |
| Capex / Sales | 20.93% | 38.04% | 22.35% | 22.98% | 22.85% | 7.94% | 5.93% | 5.31% |
| Announcement Date | 3/2/20 | 2/25/21 | 2/25/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
153.6
USD
Average target price
268.4
USD
Spread / Average Target
+74.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.85% | 16.05B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B | |
| -24.71% | 8.24B |
- Stock Market
- Equities
- BGNE Stock
- Financials BeiGene, Ltd.
